Potential treatments of COVID-19: Drug repurposing and therapeutic interventions

被引:7
作者
Raghav, Pawan Kumar [1 ]
Mann, Zoya [2 ]
Ahluwalia, Simran Kaur [3 ]
Rajalingam, Raja [1 ]
机构
[1] Univ Calif San Francisco, Dept Surg, Immunogenet & Transplantat Lab, San Francisco, CA 94143 USA
[2] BioExIn, Delhi, India
[3] Amity Univ, Amity Inst Biotechnol, Sect 125, Noida, Uttar Pradesh, India
关键词
COVID-19; SARS-CoV-2; Vaccines; Clinical trials; Drug repurposing; RESPIRATORY SYNDROME CORONAVIRUS; SPIKE PROTEIN; CONVALESCENT PLASMA; CAMOSTAT MESILATE; VIRAL-INFECTIONS; SERINE-PROTEASE; GRAPHENE OXIDE; NUCLEAR IMPORT; DENGUE VIRUS; DISEASE; 2019;
D O I
10.1016/j.jphs.2023.02.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The infection is caused when Spike-protein (S-protein) present on the surface of SARS-CoV-2 interacts with human cell surface receptor, Angiotensin-converting enzyme 2 (ACE2). This binding facilitates SARS-CoV-2 genome entry into the human cells, which in turn causes infection. Since the beginning of the pandemic, many different therapies have been developed to combat COVID-19, including treatment and prevention. This review is focused on the currently adapted and certain other potential therapies for COVID-19 treatment, which include drug repurposing, vaccines and drug-free therapies. The efficacy of various treatment options is constantly being tested through clinical trials and in vivo studies before they are made medically available to the public. (c) 2023 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.
引用
收藏
页码:1 / 21
页数:21
相关论文
共 282 条
[61]   Favipiravir as a potential countermeasure against neglected and emerging RNA viruses [J].
Delang, Leen ;
Abdelnabi, Rana ;
Neyts, Johan .
ANTIVIRAL RESEARCH, 2018, 153 :85-94
[62]   Vitamin D deficiency is associated with COVID-19 positivity and severity of the disease [J].
Demir, Mustafa ;
Demir, Fadime ;
Aygun, Hatice .
JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (05) :2992-2999
[63]   New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? [J].
Devaux, Christian A. ;
Rolain, Jean-Marc ;
Colson, Philippe ;
Raoult, Didier .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (05)
[64]   Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series [J].
Doi, Kent ;
Ikeda, Mahoko ;
Hayase, Naoki ;
Moriya, Kyoji ;
Morimura, Naoto .
CRITICAL CARE, 2020, 24 (01)
[65]   The Natural Compound Homoharringtonine Presents Broad Antiviral Activity In Vitro and In Vivo [J].
Dong, Hui-Jun ;
Wang, Zhao-Hua ;
Meng, Wen ;
Li, Cui-Cui ;
Hu, Yan-Xin ;
Zhou, Lei ;
Wang, Xiao-Jia .
VIRUSES-BASEL, 2018, 10 (11)
[66]   The spike protein of SARS-CoV - a target for vaccine and therapeutic development [J].
Du, Lanying ;
He, Yuxian ;
Zhou, Yusen ;
Liu, Shuwen ;
Zheng, Bo-Jian ;
Jiang, Shibo .
NATURE REVIEWS MICROBIOLOGY, 2009, 7 (03) :226-236
[67]   Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection [J].
Dyall, Julie ;
Coleman, Christopher M. ;
Hart, Brit J. ;
Venkataraman, Thiagarajan ;
Holbrook, Michael R. ;
Kindrachuk, Jason ;
Johnson, Reed F. ;
Olinger, Gene G., Jr. ;
Jahrling, Peter B. ;
Laidlaw, Monique ;
Johansen, Lisa M. ;
Lear-Rooney, Calli M. ;
Glass, Pamela J. ;
Hensley, Lisa E. ;
Frieman, Matthew B. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (08) :4885-4893
[68]   Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study [J].
Elfiky, Abdo A. .
LIFE SCIENCES, 2020, 253
[69]   Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model [J].
Fan, Hua-Hao ;
Wang, Li-Qin ;
Liu, Wen-Li ;
An, Xiao-Ping ;
Liu, Zhen-Dong ;
He, Xiao-Qi ;
Song, Li-Hua ;
Tong, Yi-Gang .
CHINESE MEDICAL JOURNAL, 2020, 133 (09) :1051-1056
[70]   Baricitinib for COVID-19: a suitable treatment? [J].
Favalli, Ennio G. ;
Biggioggero, Martina ;
Maioli, Gabriella ;
Caporali, Roberto .
LANCET INFECTIOUS DISEASES, 2020, 20 (09) :1012-1013